https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19876 Tue 09 Jun 2020 09:48:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17308 Sat 24 Mar 2018 08:01:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18434 Sat 24 Mar 2018 07:59:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21562 Sat 24 Mar 2018 07:59:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21565 Sat 24 Mar 2018 07:59:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20890 Sat 24 Mar 2018 07:57:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20903 Sat 24 Mar 2018 07:57:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19855 Sat 24 Mar 2018 07:57:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20586 Sat 24 Mar 2018 07:55:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21121 Sat 24 Mar 2018 07:54:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27963 Sat 24 Mar 2018 07:38:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27952 T, MTHFR 1298A>C, MTRR 66A>G, MTR 2756A>G, MTR 5049C>A, and CBS 2199 T>C). Maternal folic acid use was ascertained via questionnaire. ORs were estimated using unconditional logistic regression. Case–parent trio analyses were also undertaken. Results: There was weak evidence of a reduced risk of CBT for the MTRR 66GG genotype in the child or father: ORs 0.71 [95% confidence interval (CI), 0.48–1.07]; 0.54 (95% CI, 0.34–0.87), respectively. Maternal prepregnancy folic acid supplementation showed a stronger negative association with CBT risk where the child, mother, or father had the MTRR 66GG genotype (P_interaction = 0.07, 0.10, and 0.18, respectively). Conclusions: Evidence for an association between folate pathway genotypes and CBT is limited in this study. There was possible protection by the MTRR 66GG genotype, particularly when combined with maternal prepregnancy folic acid supplementation; these results are novel and require replication. Impact: The possible interaction between folic acid supplementation and MTRR 66A>G, if confirmed, would strengthen evidence for prepregnancy folate protection against CBT.]]> Sat 24 Mar 2018 07:38:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28102 Sat 24 Mar 2018 07:24:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26915 T, MTHFR 1298A>C, MTRR 66A>G, MTR 2756 A>G, MTR 5049 C>A, CBS 844 Ins68, and CBS 2199 T>C) were genotyped in children and their parents. Information on prepregnancy maternal folic acid supplement use was collected. ORs were estimated with unconditional logistic regression adjusted for frequency-matched variables and potential confounders. Case-parent trios were also analyzed. Results: There was some evidence of a reduced risk of ALL among children who had, or whose father had, the MTRR 66GG genotype: ORs 0.60 [95% confidence interval (CI) 0.39-0.91] and 0.64 (95% CI, 0.40-1.03), respectively. The ORs for paternal MTHFR 677CT and TT genotypes were 1.41 (95% CI, 1.02-1.93) and 1.81 (95% CI, 1.06-3.07). ORs varied little by maternal folic acid supplementation. Conclusions: Some folate pathway gene polymorphisms in the child or a parent may influence ALL risk. While biologically plausible, underlying mechanisms for these associations need further elucidation. Impact: Folate pathway polymorphisms may be related to risk of childhood ALL, but larger studies are needed for conclusive results.]]> Sat 24 Mar 2018 07:23:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22801 Sat 24 Mar 2018 07:12:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23994 Sat 24 Mar 2018 07:10:24 AEDT ]]>